Butterfly Medical Raises $21 Million in Series C Funding
Top Picks
Stay Ahead of the Market
Get the latest startup funding, hiring trends and global opportunities delivered to your inbox every week.
Butterfly Medical has raised $21 million in a Series C funding round as the company expands development of its non-surgical treatment solution for benign prostatic hyperplasia (BPH).
Investors in the round included the European Innovation Council, Junson Capital, MedVenture, and New Rhein Healthcare Investors.
The company said the funding will be used to expand operations and support ongoing product development efforts.
Company Focuses on Non-surgical BPH Treatment
Butterfly Medical develops medical devices designed to treat benign prostatic hyperplasia, commonly known as BPH. The condition affects prostate gland enlargement and can lead to urinary symptoms in aging men.
The company’s flagship device is designed to restore natural urinary flow without surgery. According to Butterfly Medical, the solution aims to provide long-term symptom relief while improving patient quality of life.
Device Holds CE Mark Certification
Butterfly Medical stated that its device has received CE Mark certification in Europe.
However, the product has not yet received approval in the United States. The company noted that the device is currently limited to investigational use under U.S. federal law.
Company Continues Development of Medical Technology Platform
The company is led by Patrick MacCarthy.
Butterfly Medical said it remains focused on advancing minimally invasive treatment technologies for urological conditions while expanding its presence in international healthcare markets.
